Albany, NY (PRWEB) February 27, 2014
Epilepsy Therapeutics to 2019 in Asia-Pacific Market, which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
View Full Report With Complete TOC at http://www.researchmoz.us/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability-report.html
The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope.
Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan.
Browse Other Published Reports By GBI Research at http://www.researchmoz.us/publisher/gbi-research-2.html
The report includes:
A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target. Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends Key drivers and restraints that have had and are expected to have a significant impact upon the market
Originally posted here:
Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show ...